Jennerex to the moment opener matter on JX-594 End 1 administer escalation clinical scan at ASGCT Annual Rendezvous
Jennerex, Inc., a clinical-stage cancer biotherapeutics group, today announced that pivotal details from its JX-594 intravenous supervision Aspect 1 administer escalation clinical reading commitment be presented at the American Group of Gene and Cubicle Remedial programme (ASGCT) Annual Get-together fetching in the right May 19-22, 2010, in Washington DC.
The show details are as follows:
Condensation #33: "Demonstration of Execution and Antitumoral Undertaking of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, Following a Unattached Intravenous Infusion in Patients with Refractory Metastatic Cancers"Oral proffering to be made on May 20, 2010, 2:00 p.m. EDT at near David H. Kirn, M.D., president and chief number one policeman of Jennerex, in the "Cancer-Oncolytic Viruses I" hearing.
AUTHORITY Jennerex, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
